Reuters logo
BRIEF-Insys Therapeutics reports Q4 adjusted earnings of $0.03/shr
2017年4月3日 / 中午11点36分 / 6 个月前

BRIEF-Insys Therapeutics reports Q4 adjusted earnings of $0.03/shr

April 3 (Reuters) - Insys Therapeutics Inc

* Insys Therapeutics reports fourth quarter and year end 2016 results

* Q4 adjusted non-GAAP earnings per share $0.03

* Q4 revenue $54.9 million versus I/B/E/S view $51.2 million

* Q4 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S

* Q4 loss per share $0.05

* Insys Therapeutics Inc - insys management will not hold a conference call for Q4 and full year 2017

* Insys Therapeutics Inc says for Q1 of 2017, company experienced an approximate 32 percent decline in subsys scripts as compared Q4 of 2016

* Insys Therapeutics - Saeed Motahari will become president and chief executive officer and be appointed to board of directors, effective April 17, 2017

* Says for Q1 of 2017, company experienced an approximate 32 percent decline in subsys scripts as compared Q4 of 2016

* Insys Therapeutics Inc says with recent clarity on scheduling of Syndros, targeting a launch in second half of 2017

* Insys Therapeutics Inc says targeting an NDA filing by end-2017 for Buprenorphine Sublingual spray for treatment of moderate to acute pain

* Insys Therapeutics - anticipates “commensurate impact” on net revenue for Q1‘17 due to decline in subsys scripts seen in Q1‘17 compared to Q4‘16 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below